Actinium-225 clinical trials
How each study uses Actinium-225 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Actinium-225 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 3
Aktis Oncology, Inc. (3) · Alpha-9 Oncology USA Inc. (2) · Peking University Cancer Hospital & Institute (2) · Eli Lilly and Company (1) · Full-Life Technologies UK Limited (1) · AstraZeneca (1) · PeptiDream Inc. (1) · University College, London (1)
Often tested with
Tested in the same studies.
PD-32766D (1) · Lutetium-177 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Actinium-225.
- Dec 2026A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line TreatmentPhase 1 · Peking University Cancer Hospital & Institute
- Sep 2027[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate CancerPhase 1 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses Actinium-225 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsRecruitingPhase 1Aktis Oncology, Inc.NCT07020117Written as [225Ac]Ac-AKY-1189 (therapeutic)
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METRecruitingPhase 1/2Full-Life Technologies UK LimitedNCT07873450Written as [225Ac]Ac-FL-261
- A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1Aktis Oncology, Inc.NCT07581184Written as [225Ac]Ac-AKY-2519 (therapeutic)
- A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid TumorsRecruitingPhase 1Aktis Oncology, Inc.NCT07887971Written as [225Ac]Ac-AKY-2519 (therapeutic)
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)RecruitingPhase 3AstraZenecaNCT07611110Written as Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])
- A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell CarcinomaRecruitingPhase 1PeptiDream Inc.NCT07688187Written as PD-32766T (an Actinium-225 [225Ac] labeled peptide)
- A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid TumorsRecruitingPhase 1Alpha-9 Oncology USA Inc.NCT07661641Written as [225Ac]Ac-A9-0642
- ACTinium in Castrate-RESistant Prostate Cancer After LUTEtiumRecruitingPhase 1/2University College, LondonNCT07414940Written as Actinium (225Ac) rhPSMA-10.1
- A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line TreatmentRecruitingPhase 1Peking University Cancer Hospital & InstituteNCT07413042Written as [225Ac]Ac-DOTATATE
- A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-NensRecruitingPhase 1Peking University Cancer Hospital & InstituteNCT06732505Written as [225Ac]Ac-DOTATATE
- [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT06229366Written as [Ac-225]-PSMA-62 (mCRPC)
- A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaTerminatedPhase 1Alpha-9 Oncology USA Inc.NCT07076550Written as [225Ac]Ac-A9-3408
- A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedPhase 1Fusion Pharmaceuticals Inc.NCT03746431Written as [225Ac]-FPI-1434 Injection multi-dose
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid TumorsOct 22, 2026NCT07887971